Shahinaz M Gadalla1, Youjin Wang2, Tao Wang3, Olusegun O Onabajo4, A Rouf Banday4, Adeola Obajemu4, Ezgi Karaesman5, Lara Sucheston-Campbell5, Theresa Hahn6, Jennifer A Sees7, Stephen R Spellman7, Stephanie J Lee8, Hormuzd A Katki9, Ludmila Prokunina-Olsson4. 1. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA. Electronic address: gadallas@mail.nih.gov. 2. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA. 3. Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA; Center for International Blood and Marrow Transplant Research Milwaukee, WI, USA. 4. Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA. 5. College of Pharmacy, Ohio State University Columbus, OH, USA. 6. Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 7. Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA. 8. Center for International Blood and Marrow Transplant Research Milwaukee, WI, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 9. Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA.
Abstract
BACKGROUND: The interferon lambda 4 gene (IFNL4) regulates immune responses by controlling the production of IFNλ4, a type III interferon. We hypothesised that IFNλ4 could play a role in infection clearance or alloreactivity in patients with acute leukaemia who received a myeloablative 10/10 HLA-matched haematopoietic stem-cell transplantation (HSCT). Therefore, we aimed to assess the association between recipient and donor IFNL4 genotype with post-HSCT survival outcomes in patients with acute leukaemia. METHODS: We did a two-stage retrospective cohort study using the Center for International Blood and Marrow Transplant Research (CIBMTR) repository and database, in which nearly all patients underwent the procedure in the USA. We included patients with acute myeloid leukaemia or acute lymphocytic leukaemia, who received a HSCT at any age from an unrelated 10/10 HLA-matched donor, with a myeloablative conditioning regimen, between Jan 1, 2000, and Dec 31, 2008, and had a pre-HSCT recipient or donor blood sample available. The discovery dataset included patients from an existing National Cancer Institute (NCI) cohort of the CIBMTR database, in which donor and recipient IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) were genotyped with TaqMan assays. According to their genotype, donors and recipients were categorised into IFNL4-positive, if they had at least one copy of the allele that supports the production of IFNλ4, or IFNL4-null for the analyses. The findings were independently validated with patients from the DISCOVeRY-BMT cohort (validation dataset) with existing Illumina array genotype data. We also did a combined analysis using data from patients included in both the NCI and DISCOVeRY-BMT cohorts. FINDINGS: We assessed 404 patients (who had a HSCT from Jan 9, 2004, to Dec 26, 2008) in the discovery dataset and 1245 patients in the validation dataset (HSCT Jan 7, 2000, to Dec 26, 2008). The combined analysis included 1593 overlapping participants in both cohorts. Donor, but not recipient IFNL4-positive genotype was associated with increased risk of non-relapse mortality (HR 1·60, 95% CI 1·23-2·10; p=0·0005 in the discovery dataset; 1·22, 1·05-1·40; p=0·0072 in the validation dataset; and 1·27, 1·12-1·45; p=0·0001 in the combined dataset). Associations with post-HSCT overall survival were as follows: HR 1·24, 95% CI 1·02-1·51; p=0·034 in the discovery dataset; 1·10, 0·98-1·20; p=0·10 in the validation dataset; and 1·11, 1·02-1·22; p=0·018 in the combined dataset. INTERPRETATION: Prioritising HSCT donors with the IFNL4-null genotype might decrease non-relapse mortality and improve overall survival without substantially limiting the donor pool. If these findings are validated, IFNL4 genotype could be added to the donor selection algorithm. FUNDING: The National Cancer Institute Intramural Research Program. For full funding list see Acknowledgments.
BACKGROUND: The interferon lambda 4 gene (IFNL4) regulates immune responses by controlling the production of IFNλ4, a type III interferon. We hypothesised that IFNλ4 could play a role in infection clearance or alloreactivity in patients with acute leukaemia who received a myeloablative 10/10 HLA-matched haematopoietic stem-cell transplantation (HSCT). Therefore, we aimed to assess the association between recipient and donor IFNL4 genotype with post-HSCT survival outcomes in patients with acute leukaemia. METHODS: We did a two-stage retrospective cohort study using the Center for International Blood and Marrow Transplant Research (CIBMTR) repository and database, in which nearly all patients underwent the procedure in the USA. We included patients with acute myeloid leukaemia or acute lymphocytic leukaemia, who received a HSCT at any age from an unrelated 10/10 HLA-matched donor, with a myeloablative conditioning regimen, between Jan 1, 2000, and Dec 31, 2008, and had a pre-HSCT recipient or donor blood sample available. The discovery dataset included patients from an existing National Cancer Institute (NCI) cohort of the CIBMTR database, in which donor and recipient IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) were genotyped with TaqMan assays. According to their genotype, donors and recipients were categorised into IFNL4-positive, if they had at least one copy of the allele that supports the production of IFNλ4, or IFNL4-null for the analyses. The findings were independently validated with patients from the DISCOVeRY-BMT cohort (validation dataset) with existing Illumina array genotype data. We also did a combined analysis using data from patients included in both the NCI and DISCOVeRY-BMT cohorts. FINDINGS: We assessed 404 patients (who had a HSCT from Jan 9, 2004, to Dec 26, 2008) in the discovery dataset and 1245 patients in the validation dataset (HSCT Jan 7, 2000, to Dec 26, 2008). The combined analysis included 1593 overlapping participants in both cohorts. Donor, but not recipient IFNL4-positive genotype was associated with increased risk of non-relapse mortality (HR 1·60, 95% CI 1·23-2·10; p=0·0005 in the discovery dataset; 1·22, 1·05-1·40; p=0·0072 in the validation dataset; and 1·27, 1·12-1·45; p=0·0001 in the combined dataset). Associations with post-HSCT overall survival were as follows: HR 1·24, 95% CI 1·02-1·51; p=0·034 in the discovery dataset; 1·10, 0·98-1·20; p=0·10 in the validation dataset; and 1·11, 1·02-1·22; p=0·018 in the combined dataset. INTERPRETATION: Prioritising HSCT donors with the IFNL4-null genotype might decrease non-relapse mortality and improve overall survival without substantially limiting the donor pool. If these findings are validated, IFNL4 genotype could be added to the donor selection algorithm. FUNDING: The National Cancer Institute Intramural Research Program. For full funding list see Acknowledgments.
Authors: Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien Journal: Nat Genet Date: 2013-01-06 Impact factor: 38.330
Authors: Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti Journal: Blood Date: 2007-09-04 Impact factor: 22.113
Authors: Adeola A Obajemu; Nina Rao; Kari A Dilley; Joselin M Vargas; Faruk Sheikh; Raymond P Donnelly; Reed S Shabman; Eric G Meissner; Ludmila Prokunina-Olsson; Olusegun O Onabajo Journal: J Immunol Date: 2017-10-25 Impact factor: 5.422
Authors: Effie W Petersdorf; Mari Malkki; Colm O'hUigin; Mary Carrington; Ted Gooley; Michael D Haagenson; Mary M Horowitz; Stephen R Spellman; Tao Wang; Philip Stevenson Journal: N Engl J Med Date: 2015-08-13 Impact factor: 91.245
Authors: Wei Tang; Tiffany A Wallace; Ming Yi; Cristina Magi-Galluzzi; Tiffany H Dorsey; Olusegun O Onabajo; Adeola Obajemu; Symone V Jordan; Christopher A Loffredo; Robert M Stephens; Robert H Silverman; George R Stark; Eric A Klein; Ludmila Prokunina-Olsson; Stefan Ambs Journal: Clin Cancer Res Date: 2018-07-16 Impact factor: 12.531
Authors: Shahinaz M Gadalla; Geraldine Aubert; Tao Wang; Michael Haagenson; Stephen R Spellman; Lingxiao Wang; Hormuzd A Katki; Sharon A Savage; Stephanie J Lee Journal: Blood Date: 2018-04-09 Impact factor: 22.113
Authors: Anita D'Souza; Caitrin Fretham; Stephanie J Lee; Mukta Arora; Janet Brunner; Saurabh Chhabra; Steven Devine; Mary Eapen; Mehdi Hamadani; Parameswaran Hari; Marcelo C Pasquini; Waleska Perez; Rachel A Phelan; Marcie L Riches; J Douglas Rizzo; Wael Saber; Bronwen E Shaw; Stephen R Spellman; Patricia Steinert; Daniel J Weisdorf; Mary M Horowitz Journal: Biol Blood Marrow Transplant Date: 2020-05-11 Impact factor: 5.609
Authors: Shahinaz M Gadalla; Tao Wang; David Loftus; Lyssa Friedman; Casey Dagnall; Michael Haagenson; Stephen R Spellman; Ljubomir Buturovic; Marsha Blauwkamp; Jason Shelton; Katharina Fleischhauer; Katharine C Hsu; Michael R Verneris; Damjan Krstajic; Belynda Hicks; Kristine Jones; Stephanie J Lee; Sharon A Savage Journal: Bone Marrow Transplant Date: 2017-12-21 Impact factor: 5.483
Authors: Ludmila Prokunina-Olsson; Robert D Morrison; Adeola Obajemu; Almahamoudou Mahamar; Sungduk Kim; Oumar Attaher; Oscar Florez-Vargas; Youssoufa Sidibe; Olusegun O Onabajo; Amy A Hutchinson; Michelle Manning; Jennifer Kwan; Nathan Brand; Alassane Dicko; Michal Fried; Paul S Albert; Sam M Mbulaiteye; Patrick E Duffy Journal: Genes Immun Date: 2021-04-13 Impact factor: 2.676